Hepatic Carcinoma Clinical Trial
Official title:
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
The aim of the multi-centre study is to evaluate correctly the impact of three dimensional visualization on operation strategy and complications for complex hepatic carcinoma.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | June 1, 2019 |
Est. primary completion date | June 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. 18 years= Age =70 years 2. Compling with the diagnosis criteria of complex hepatic carcinoma. 3. Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled 4. Preoperative liver function is Child - Pugh grade A or B. 5. The patients are volunteered for the study. Exclusion Criteria: 1. Patients with mental illness. 2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.) 3. The patients refused to take part in the study. 4. There are other co-existed malignant tumors. 5. Benign liver diseases. |
Country | Name | City | State |
---|---|---|---|
China | Zhujiang Hospital of The Southern Medical University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Zhujiang Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact on operation strategy of three dimensional visualization technique | Firstly, the operation strategies based on original CT or MRI image data will be made by the team, Secondly, the operation strategies based on three dimensional reconstruction models will be made by the team, then, actually surgical strategies will be recorded. The change of operation strategy will be assessed by comparing the strategy of the 2D model and 3D model. The change rate of operation strategy will be recorded and presented as percentage. | 2 year | |
Primary | Impact on complication of three dimensional visualization technique | The complications are refer to the classification of Clavien-Dindo, including postoperative bleeding, biliary fistula, ascites, postoperative liver failure, renal dysfunction, pleural effusion, abdominal cavity infection, abdominal abscess, incision infection, the occurrence cases of each complication (number) will be recorded. | 2 year | |
Secondary | Blood routine examination (the 1th, 3 th, 5th, 7th) | Hemoglobin (g/L), Platelet(109/L), and neutrophilic granulocyte percentage (%) | 2 year | |
Secondary | Urine routines (the 1th, 3 th,5th, 7th) | Urine specific gravity, urine protein(mg/dl), urine sugar(mmol/L), leukocytes in urine(number/ul), urine erythrocyte(number/ul) | 2 year | |
Secondary | Stool Routine (the 1th, 3 th,5th, 7th) | Defecate occult blood test, Microorganisms (mold, parasites, etc.) | 2 year | |
Secondary | Blood biochemistry (the 1th, 3 th,5th, 7th) | Serum albumin(g/L), serum pre-albumin(g/L), serum globulin(g/L), total bilirubin(µmol/L), direct bilirubin(µmol/L),serum glutamic-oxaloacetic transaminase (AST, IU/L), serum glutamic pyruvic transaminase (ALT, IU/L), alkaline phosphatase (ALP, IU/L), gamma glutamyl transpeptidase(r-GGT, IU/L) ,Serum creatinine(µmol/L), Urea(mmol/L), Blood sugar(mmol/L) | 2 year | |
Secondary | Tumor marker | Alpha fetoprotein(AFP, ng/L), Carbohydrate antigen-199(CA-199, ku/L), Carbohydrate antigen-125(CA-125, ku/L), Carcinoembryonic antigen (CEA, ng/L), Carbohydrate antigen-153(CA-153, ku/L) | 2 year | |
Secondary | The blood coagulation function (the 1th, 3th, 5th, 7th) | prothrombin time (PT, s), partial thromboplastin time (APTT), international normalized ratio (INR), plasma prothrombin activity (PTA, %), fibrinogen (FIB, g/L), d—dimer(mg/L) | 2 year | |
Secondary | Inflammatory biomarkers | C-reactive protein, procalcitonin | 2 year | |
Secondary | Preoperative viral loading | HBV- DNA?HCV- RNA | 2 year | |
Secondary | Postoperative results of paraffin wax and immunohistochemical index | AFP?Ki67?CK18?CK19?Hepatocyte | 2 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03253250 -
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
|
Phase 4 | |
Terminated |
NCT01760616 -
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
|
Phase 4 | |
Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
Not yet recruiting |
NCT03149523 -
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
|
N/A | |
Recruiting |
NCT05009550 -
ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation
|
N/A | |
Recruiting |
NCT06342414 -
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
|
||
Completed |
NCT03164382 -
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Completed |
NCT03572582 -
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT04266548 -
Arterial Base Fluorescence Segmental Positive Staining
|
N/A | |
Recruiting |
NCT03013712 -
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT01350726 -
Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan
|
N/A | |
Completed |
NCT06245798 -
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
|
||
Recruiting |
NCT06311396 -
Development of a Neuronal Microscope
|
N/A | |
Recruiting |
NCT04220944 -
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
|
Phase 1 | |
Completed |
NCT02352935 -
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
|
N/A | |
Completed |
NCT02332551 -
Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder
|
N/A | |
Completed |
NCT02834780 -
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Not yet recruiting |
NCT06182865 -
A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
|
N/A | |
Completed |
NCT05007548 -
to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
|
Phase 2 | |
Completed |
NCT03163186 -
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
|
N/A |